FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
BioSpace11h
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Eagle-Tribune22h
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials
Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...
precisionmedicineonline1d
Atalanta Therapeutics Raises $97M in Series B Financing to Advance RNAi Therapies for CNS Diseases
Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.
The University of Chicago Chronicle1d
Collaboration to provide up to $130 million to fuel drug discovery, development at UChicago
Launch of Hyde Park Discovery between UChicago, Deerfield Management to accelerate research into life-saving treatments ...
MyChesCo on MSN2d
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine
Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel ...
Hosted on MSN2d
How to Play NVO Stock After New Drug's Success in Obesity Study
Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
Allogene announces FDA cleared IND application for study of ALLO-329
Allogene Therapeutics (ALLO) announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, ...
SEED receives FDA Rare Pediatric Disease, Orphan Drug designations for ST-01156
SEED Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Orphan Drug designations to ...
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.